Its too bad there is no easy shipping solution for getting refrigerated medications from India via regular postal services:
- Lilly beats Novo Nordisk to launch weight-loss drug in India
- Mounjaro’s 5 mg vial priced at around $50, 2.5 mg at about $40
- Drug’s pricing may limit accessibility in India, analyst says
- Novo’s Wegovy already approved in India
HYDERABAD, March 21 (Reuters) - Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk for a much-awaited entry into the world’s most populous country grappling with increasing rates of obesity and diabetes.
U.S.-based Lilly (LLY.N), opens new tab and Danish Novo Nordisk (NOVOb.CO), opens new tab have seen skyrocketing global demand for their innovative weight-loss drugs, with investor interest also boosting the drugmakers’ valuations.
Mounjaro, a once-weekly injection approved by India’s drug regulator, is priced at 4,375 rupees ($50.67) for a 5 mg vial and 3,500 rupees ($40.54) for a 2.5 mg vial, its lowest doses, the company told Reuters exclusively. Its highest dose is 15 mg.
A patient in India may have to spend about $200 a month when taking a weekly dose of 5 mg, subject to doctor’s prescription.
Mounjaro carries a list price of $1,086.37 for each monthly fill in the U.S., but the amount patients pay largely depends on their insurance plan. Lilly also offers 5 mg, 7.5 mg and 10 mg vials of Zepbound, with prices around $499 for a month’s supply if customers pay directly in cash without any third-party entities.
Read the full story: Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market